Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
45 results about "Angiotensinamide" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Angiotensinamide (INN; BAN and USAN angiotensin amide) is a potent vasoconstrictor used as a cardiac stimulant. It is a derivative of angiotensin II.
Use of vitamin Ds to treat kidney disease
InactiveUS20050124591A1Reduce inflammationSuppression problemBiocideUrinary disorderDiseaseAngiotensin Receptor Blockers
Disclosed are compositions containing a VDRA / Vitamin D analog to treat or prevent kidney disease, including chronic kidney disease. The present invention also relates to methods of treating kidney disease by administering to a patient a pharmaceutical composition containing a therapeutically effective amount of a VDRA / Vitamin D analog. Compositions according to the invention include a VDRA / Vitamin D analog and at least one of the following agents: an ACE inhibitor, an angiotensin (II) receptor blocker (ARB) and aldosterone blocker in therapeutically effective amounts to inhibit renin production or inhibit activation of the renin-angiotensin-aldosterone system. Preferred compositions contain paricalcitol with at least one of these other agents. Such combinations can avoid ACE inhibition escape and aldosterone escape with subsequent increase in angiotensin (II) and aldosterone generation.
Owner:ABBOTT LAB INC
Use of Vitamin Ds to treat kidney disease
InactiveUS20050148557A1Reduce inflammationSuppression problemBiocideUrinary disorderDiseaseAldosterone escape
Disclosed are compositions containing a VDRA / Vitamin D analog to treat or prevent kidney disease, including chronic kidney disease. The present invention also relates to methods of treating kidney disease by administering to a patient a pharmaceutical composition containing a therapeutically effective amount of a VDRA / Vitamin D analog. Compositions according to the invention include a VDRA / Vitamin D analog and at least one of the following agents: an ACE inhibitor, an angiotensin (II) receptor blocker (ARB) and aldosterone blocker in therapeutically effective amounts to inhibit renin production or inhibit activation of the renin-angiotensin-aldosterone system. Preferred compositions contain paricalcitol with at least one of these other agents. Such combinations can avoid ACE inhibition escape and aldosterone escape with subsequent increase in angiotensin (II) and aldosterone generation.
Owner:UNIVERSITY OF CHICAGO
One-step method based solid-phase polypeptide synthesis method
ActiveCN103374054AHigh purityHigh yieldPeptide preparation methodsChemical reactionSynthesis methods
The invention discloses a one-step method based solid-phase polypeptide synthesis method. The technology of blowing in nitrogen or insert gases to volatilize a volatile solvent and reduce the temperature is adopted in each condensation reaction of connected protected amino acids, the nitrogen or the insert gases are filled into a reaction mixture so that the volatile solvent is volatilized and the temperature of a reaction system can be maintained at 15-20 DEG C, after an auxiliary condensing agent is added to start the condensation reaction, the temperature of the condensation reaction system is always stabilized at 22-28 DEG C by a heat insulation device, and during condensation of protected amino acids, the amino acids are unnecessary to be activated at low temperature in an activator and then be transferred to a condensation reactor, thus all the chemical reactions for synthesizing polypeptide are continuously completed in the same reactor in sequence. The method for synthesizing angiotensinamide is environment-friendly and efficient, has low requirements for equipment and can be applied to large-scale industrial production.
Owner:SPH NO 1 BIOCHEM & PHARMA CO LTD
Angiotensin peptide-carrier conjugates and uses thereof
InactiveUS7115266B2Promote formationImprove complianceVirusesPeptide/protein ingredientsVirus-like particleAngiotensinogen mrna
Owner:CYTOS BIOTECHNOLOGY AG
Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
InactiveUS20140142149A1Improves friabilityEasy to compressBiocideSenses disorderEndothelin receptor antagonistAgonist
Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.
Owner:LIGAND PHARMA INC
Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
ActiveUS20150164865A1Lower systolic blood pressureLower diastolic blood pressureBiocideSenses disorderDiseaseAngiotensin II receptor type 1
Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.
Owner:LIGAND PHARMA INC
Method of using combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor
ActiveUS20110213004A1Reduce the impactIncreased riskBiocideMetabolism disorderHMG-CoA reductaseSide effect
Disclosed herein is a combination therapy and a combination preparation of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor characterized in that the angiotensin-II-receptor blocker is absorbed substantially later than the HMG-CoA reductase inhibitor. As the angiotensin-II-receptor blocker and the HMG-CoA reductase inhibitor are released at different times, the present combination therapy prevents competitive inhibition between the two drugs and side effects, as well as simultaneously provides synergistic effects for each active ingredient and convenience of taking the drugs.
Owner:HANALL PHARMA CO LTD
Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof
The prior art lacks a formulation, application or product of D-Ala7-Angiotensin-(1-7) (A-779) and analogues and derivatives, D-Pro7-Angiotensin-(1-7) and analogues or derivatives or of Ang-(1-7) analogues or derivatives using ciclodextrines, lipossomes, biodegradable polymers and its derivatives for the study or treatment of arterial hypertension and other cardiovascular diseases, wounds, burns, erithema, tumors, diabetes mellitus, sperm mobility, nephropathy, gastrointestinal and gynaecological disorders, angiogenesis, angioplatsy, alopecia and blood diseases in warm blooded animals, or as ligands for de G-protein-coupled receptor MAS. This characterizes the present invention as a more effective option for the study and treatment of pathologies associated or not to this receptor. A combination of two different technologies are provided: the molecular encapsulament of the peptide angiotensin-(1-7) and its analogues and derivates in cyclodextrin and the microencapsulament in biodegradable polymers and lipossomes. It is also characterized by the increase of this peptides and its analogues and derivatives using the formulation.
Owner:UNIVERSIDADE FEDERAL DE MINAS GERAIS
3-pyrrole carboxylic acid derivatives, and preparing method and application thereof
InactiveCN103420890AHas receptor antagonistic effectReceptor antagonismOrganic active ingredientsNervous disorderArginineAcid derivative
The invention relates to 3-pyrrole carboxylic acid derivatives, and a preparing method and an application thereof, and particularly relates to the 3-pyrrole carboxylic acid derivatives having a structure represented by formula I and pharmaceutically acceptable salts thereof and the preparing method of the derivatives, pharmaceutical compositions with the 3-pyrrole carboxylic acid derivatives having the structure represented by the formula I and the pharmaceutically acceptable salts of the 3-pyrrole carboxylic acid derivatives as active ingredients, and applications of the pharmaceutical compositions in prevention or treatment of diseases related with an arginine vasopressin V1a receptor, an arginine vasopressin V1b receptor, an arginine vasopressin V2 receptor, a sympathetic nervous system or a renin-angiotensin-aldosterone system.
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH
Desloratadine derivatives, and preparation method and application thereof
The invention relates to desloratadine derivatives, and a preparation method and application thereof, particularly desloratadine derivatives disclosed as Formula I and pharmaceutically acceptable salts thereof and a preparation method thereof, and application of the desloratadine derivatives disclosed as Formula I and pharmaceutically acceptable salts thereof as active effective ingredients of active pharmaceutical compositions in preventing and treating diseases related to arginine vasopressin V1a receptor, arginine vasopressin V1b receptor, arginine vasopressin V2 receptor, sympathetic nervous system or renin-angiotensin-aldosterone system.
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH
Multi-cascade antihypertensive drug composition containing folic acid
InactiveCN106310278AGood antihypertensive effectEffective protectionOrganic active ingredientsCardiovascular disorderThiazide diureticTherapeutic effect
The invention relates to a drug composition. The drug composition consists of an effective treating amount of calcium antagonist (CCB), an angiotensin II receptor blocker (ARB), a thiazide diuretic, a folic acid compound and a pharmaceutically acceptable carrier, wherein the content of the CCB is 2-240 mg, the content of the ARB is 4-600 mg, the content of the thiazide diuretic is 0.625-25 mg, and the content of the folic acid compound is 0.4-0.4 mg. The drug composition has the advantages that the drug composition can effectively improve the treatment effect of reducing blood pressure of class-2 and class-3 hypertensive patients, strengthen the effect of protecting target organs of the patients and reduce the occurrence risk of cerebral apoplexy complications caused by high blood pressure. In addition, the drug composition can be conveniently taken by patients, the treatment compliance is greatly improved, and the medical costs can be also reduced.
Owner:SHENZHEN AUSA PHARM CO LTD +1
Process for the preparation of angiotensin ii antagonistic compounds
A process for the preparation of angiotensin II antagonists and novel intermediates useful for the synthesis thereof.
Owner:DIPHARMA SPA
Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers
InactiveCN101534798AReduce healingHigh antihypertensive effectOrganic active ingredientsUrinary disorderControlled releaseSide effect
Owner:韩诺生物制约株式会社
Benzimidazole derivative and use as angiotensin ii antagonist
InactiveCN101151260AEasy to solveGood treatment effectOrganic active ingredientsOrganic chemistryBenzimidazole derivativeCarboxylic acid
The present invention provides (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-cyclopropyl-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate represented by the formula: which has superior properties as a pharmaceutical agent, a salt thereof, a crystal thereof, a pharmaceutical agent containing the compound, and the like.
Owner:TAKEDA PHARMA CO LTD
Sulfonamide compound, and preparation method and application thereof
InactiveCN103965162AHas receptor antagonistic effectReceptor antagonismOrganic active ingredientsNervous disorderArginineCombinatorial chemistry
The invention relates to a sulfonamide compound, and a preparation method and application thereof. Particularly, the invention relates to the sulfonamide compound with a structure shown in the formula I, an acceptable salt of the sulfonamide compound on the pharmacy, and a preparation method of the sulfonamide compound. A medicine composition uses the sulfonamide compound with the structure shown in the formula I, and the acceptable salt of the sulfonamide compound on the pharmacy as active ingredients to be used for preventing or treating diseases related to arginine vasopressin V1a receptors, arginine vasopressin V1b receptors, arginine vasopressin V2 receptors, a sympathetic nervous system or a renin-angiotensin-aldosterone system.
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH
Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor
Owner:HANALL PHARMA CO LTD
Cyclic angiotensin analogs
The invention relates to analogs of angiotensins, in particular to cyclised analogs having Ang(1-8) agonistic or antagonistic activity and to cyclised Ang(1-7) analogs with agonistic or antagonistic activity and displaying improved proteolytic resistance compared to their linear counterparts. Provided is a cyclic angiotensin peptide analog comprising a thioether-bridge linkage between the amino acids corresponding to positions Tyr4 and Pro7 in naturally occurring Angiotensin. Also provided is the use of analogs in therapy, for example hypertension.
Owner:APPLIED NANOSYST
Bisulfamide compounds as well as preparation method and use thereof
ActiveCN103936713AHas receptor antagonistic effectReceptor antagonismOrganic active ingredientsNervous disorderDiseaseArginine
The invention relates to bisulfamide compounds as well as a preparation method and use thereof, and specifically relates to bisulfamide compounds having the structure as shown in a formula I and pharmaceutically acceptable salts thereof as well as a preparation method of the bisulfamide compounds, pharmaceutical compositions with the bisulfamide compounds having the structure as shown in the formula I and the pharmaceutically acceptable salts thereof as active effective constituents and use of the pharmaceutical compositions in preventing or treating diseases associated with an arginine vasopressin V1a receptor, an arginine vasopressin V1b receptor, an arginine vasopressin V2 receptor, the sympathetic nervous system or the renin-angiotensin-aldosterone system; the formula I is as shown in the specification.
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH
Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
InactiveUS20060154976A1Good effectMaximum preventionAntibacterial agentsBiocideDepressantRisk stroke
A method of treatment of indications which can be positively influenced by inhibition of AT1 mediated effects with maintenance of AT2 receptor mediated effects of angiotensin II and by ACE inhibition, thus also increasing bradykinin mediated effects, e.g., to reduce the incidence of stroke, acute myocardial infarction or cardiovascular death, or of indications associated with the increase of AT1 receptors in the subepithelial area or increase of AT2 receptors in the epithelia, comprising coadministration of effective amounts of an angiotensin II antagonist and an ACE inhibitor, pharmaceutical compositions containing an angiotensin II antagonist together with an ACE inhibitor and the use of an angiotensin II antagonist and an ACE inhibitor for the manufacture of corresponding pharmaceutical compositions.
Owner:BOEHRINGER INGELHEIM PHARM KG
Bisamide compounds as well as preparation method and use thereof
InactiveCN104418836AHas receptor antagonistic effectReceptor antagonismOrganic active ingredientsNervous disorderArginineIncreased aldosterone
The invention relates to compounds with two amido bonds as well as a preparation method and use of the compounds, and particularly relates to compounds with two amido bonds having structures as shown in the formula I, pharmaceutically acceptable salts of the compounds, preparation methods of the pharmaceutically acceptable salts and the compounds, a pharmaceutical composition of the compounds with the two amido bonds having the structures as shown in the formula I and the pharmaceutically acceptable salts as effective components, and use of the pharmaceutical composition in prevention or treatment of diseases related to an arginine vasopressin V1a receptor, an arginine vasopressin V1b receptor, an arginine vasopressin V2 receptor, a sympathetic nervous system or a rennin-angiotensin-aldosterone system.
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH
N-substituted benzoyl phenothiazine compounds as well as preparation method and application thereof
The invention relates to N-substituted benzoyl phenothiazine compounds as well as a preparation method and application thereof, and particularly relates to N-substituted benzoyl phenothiazine compounds having a structure as shown in a formula I described in the specification as well as a preparation method of the compounds, pharmaceutical compositions taking the N-substituted benzoyl phenothiazine compounds having a structure as shown in the formula I as active ingredients and use of the pharmaceutical compositions for preventing or treating diseases related to an arginine vasopressin V1a receptor, an arginine vasopressin V1b receptor, an arginine vasopressin V2 receptor, a sympathetic nervous system or a rennin-angiotensin-aldosterone system.
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH
Phosphate ester-containing piperazine derivative and preparation method as well as application thereof
InactiveCN102627669AReceptor antagonismOrganic active ingredientsGroup 5/15 element organic compoundsDiseasePhosphate
The invention relates to a phosphate ester-containing piperazine derivative and a preparation method as well as application thereof, in particular to one type of phosphate ester-containing piperazine derivatives with a structure shown by a formula I and a preparation method thereof, a medicinal composition with the phosphate ester-containing piperazine derivative with the structure shown by the formula I as an active ingredient and application thereof to preventing or treating diseases related to arginine vasopressin V1a receptors, arginine vasopressin V1b receptors, arginine vasopressin V2 receptors, a sympathetic nervous system or a renin-angiotensin-aldosterone system.
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH
Compositions and methods for the treatment of diseases related to the renin-angiotensin-system
ActiveUS9839668B2Improve the level ofGood effectPeptide/protein ingredientsPharmaceutical delivery mechanismDiseaseAngiotensin-converting enzyme
Owner:ALTERRAS THERAPEUTICS GMBH
Combination therapy comprising angiotensin receptor blockers and vasopressin receptor antagonists
Owner:JANSSEN PHARMA NV
Compound antihypertensive preparation and application thereof
InactiveCN105106962AImprove complianceStrengthen the synergistic antihypertensive effectOrganic active ingredientsDrageesAdjuvantAngiotensin receptor ii
The invention provides a pharmaceutical composition for treating hypertension. The pharmaceutical composition is characterized by comprising (1) angiotensin II receptor blocker, (2) diuretic metolazone, (3) calcium channel blocker and (4) pharmaceutically acceptable adjuvant materials, wherein the weight ratio among the angiotensin receptor blocker, the metolazone and the calcium channel blocker is 2-200:0.5-5:2-50. The pharmaceutical composition for treating hypertension has the advantages that the pharmaceutical composition combines the angiotensin receptor blocker, the metolazone and the calcium channel blocker, and accordingly, synergetic antihypertensive effect is enhanced, adverse reaction is reduced and compliance of patients is improved; the pharmaceutical composition is wide in application range and can be also used for patients suffering from severe renal damage; the pharmaceutical composition is applicable to mild and moderate essential hypertension, particularly secondary hypertension caused by renal damage.
Owner:XIAN LIBANG ZHAOXIN BIOTECH CO LTD
Phosphate ester-containing piperazine derivative and preparation method as well as application thereof
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH
Disulfamide phenothiazine compound, and preparation method and application thereof
The invention relates to a disulfamide phenothiazine compound, and a preparation method and an application thereof, and particularly relates to the disulfamide phenothiazine compound with a structure of a formula I shown in the specification and the preparation method thereof, a medicinal composition with the disulfamide phenothiazine compound with the structure of the formula I as an active and effective component and application of the disulfamide phenothiazine compound to preventing or treating diseases related to arginine vasopressin V1a receptors, arginine vasopressin V1b receptors, arginine vasopressin V2 receptors, a sympathetic nervous system or a renin-angiotensin-aldosterone system.
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH
Medicinal composition containing angiotensin II receptor antagonist and vitamin B
ActiveCN1286844CGood curative effectImprove protectionSenses disorderMetabolism disorderAnginaNK1 receptor antagonist
The medicine composition consists of one of AT1 receptor antagonist, its active metabolism product, ester and salt in treating effective amount of 4-800 mg, one or several kinds one B family vitamins in treating effective amount of 0.1-50 mg, and pharmaceutically acceptable carrier. The medicine composition of the present invention has the beneficial effects of raising the treating effect of blood pressure lowering AT1 receptor antagonist, strengthening the protecting effect of blood pressure lowering AT1 receptor antagonist on target organ and reducing the incidence rate of hemorrhage of the ocular fundus, angina pectoris, myocardial infarction and other complications.
Owner:SHENZHEN AUSA PHARM CO LTD +2
Medicinal composition containing angiotensin II receptor agonist and fibric acid compound
ActiveCN100584382CImprove compliancePrevent or delay damageOrganic active ingredientsMetabolism disorderDiseasePatient compliance
Owner:SHENZHEN AUSA PHARM CO LTD +2
N-substituted benzenesulfonyl phenothiazine compounds as well as preparation method and use thereof
The invention relates to N-substituted benzenesulfonyl phenothiazine compounds as well as a preparation method and application thereof, and particularly relates to N-substituted benzenesulfonyl phenothiazine compounds having a structure shown in a formula I described in the specification as well as a preparation method thereof, pharmaceutical compositions taking the N-substituted benzenesulfonyl phenothiazine compounds with a structure as shown in the formula I as active ingredients and use of the pharmaceutical compositions for preventing or treating diseases associated with an arginine vasopressin V1a receptor, an arginine vasopressin V1b receptor, an arginine vasopressin V2 receptor, a sympathetic nervous system or a rennin-angiotensin-aldosterone system.
Owner:天津天诚新药评价有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com